In conclusion, our findings highlight the feasibility and therapeutic potential of targeting the SOST-STAT3 complex for the treatment of breast cancer bone metastases and identify S6 as a promising candidate for further development as a new class of cancer therapeutic agents. Here, SOST is linked to breast carcinoma.